Brooke is an associate editor for The American Journal of Managed Care® (AJMC®). She joined AJMC in 2023, where she produces written content covering multiple disease states.
She has a BA in journalism from Seton Hall University. You can connect with Brooke on LinkedIn.
Mixed Outcomes Persist Between MA, FFS Beneficiaries: Johnie Rose, MD, PhD
April 10th 2025As Medicare Advantage (MA) enrollment grows, Johnie Rose, MD, PhD, Case Western Reserve University School of Medicine, underscores the importance of ongoing research into outcomes for MA beneficiaries vs fee-for-service (FFS) Medicare beneficiaries.
Inflammatory Diets Raise Risk of Brain Disorders
April 10th 2025Vegetables, fish oil, fruit, and high-fiber foods have anti-inflammatory effects, while low-fiber bread and animal fats are associated with pro-inflammatory effects. Diets heavier on these pro-inflammatory foods may be associated with higher risks of brain disorders.
Sociodemographic Factors Impact Cytoreductive Surgery Decisions in Advanced Ovarian Cancer
April 9th 2025Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in nonmetropolitan areas, and were unmarried had higher odds of refusing cytoreductive surgery.
Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA
April 8th 2025Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting structural damage in patients with active psoriatic arthritis (PsA).
COVID-19’s Role in Revolutionizing Remote Patient Monitoring
March 27th 2025COVID-19 served as a major catalyst for the widespread adoption of remote patient monitoring, which helps to prevent hospitalizations, improve medication adherence, and enable early interventions by helping providers prioritize high-risk patients.
Dr Toon Van Gorp: Mirvetuximab Soravtansine Should Be Global Standard for FRα+ Ovarian Cancer
March 20th 2025Toon Van Gorp, MD, PhD, a MIRASOL trial investigator, emphasizes that the final analysis reinforces the efficacy of mirvetuximab soravtansine-gynx (Elahere; AbbVie) in patients with folate receptor alpha-positive (FRα+), platinum-resistant ovarian cancer.